NasdaqCM:IKTBiotechs
A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress
Inhibikase Therapeutics (IKT) has moved into focus after fresh FDA designations and progress in its Phase 2a trial for IkT-148009 targeting Parkinson’s disease, even as ongoing financial instability remains part of the picture.
See our latest analysis for Inhibikase Therapeutics.
The recent FDA designations and Phase 2a progress appear to be feeding into momentum, with a 7 day share price return of 20.11% and a 90 day share price return of 37.50%, even though the 1 year total shareholder...